Bioneercorporation

바이오니아 · 064550

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$156.9M (₩216.5B)

Overview

Bioneer Corporation makes laboratory tools and reagents, such as DNA synthesis products, PCR instruments, and automated nucleic-acid extraction equipment, that scientists use to study and work with genes.

Its customers include universities, government research institutes, and corporate laboratories across Korea and more than fifty countries worldwide. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company also operates molecular-diagnostics and RNA-based drug-development businesses alongside its core life-science research products.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$239.2M

▲ +12.3% YoY

Operating profit · FY2025

US$11M

Turned profitable

Net income · FY2025

US$1.2M

Turned profitable

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$190.8M(₩263.2B)	US$213M(₩294B)	US$239.2M(₩330.1B)
Operating profit	US$573.7K(₩791.8M)	−US$9.7M(−₩13.4B)	US$11M(₩15.2B)
Net income	−US$5M(−₩6.9B)	−US$13.8M(−₩19B)	US$1.2M(₩1.7B)

Revenue

FY2023US$190.8M
FY2024US$213M
FY2025US$239.2M

Operating profit

FY2023US$573.7K
FY2024−US$9.7M
FY2025US$11M

Net income

FY2023−US$5M
FY2024−US$13.8M
FY2025US$1.2M

Key ratios (FY2025)

ROE

0.8%

Debt/Eq

63.0%

Op. margin

4.6%

Net margin

0.5%

Rev. YoY

▲ +12.3%

Why it matters

Bioneer conducts its probiotics business through a subsidiary called AcesBiome and its RNA-interference drug development through a subsidiary called Theragnosis, giving it a multi-entity corporate structure.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?